From patient observation to potential new therapies—Is old spironolactone a new analgesic?

  title={From patient observation to potential new therapies—Is old spironolactone a new analgesic?},
  author={Eija A Kalso},
  journal={Scandinavian Journal of Pain},
  pages={61 - 62}
  • E. Kalso
  • Published 2014
  • Medicine
  • Scandinavian Journal of Pain
In this issue of the Scandinavian Journal of Pain Heinrich Wernze nd Thomas Herdegen [1] report that spironolactone shows benficial long-term effects on pain, mood, and quality of life in 50% f the 31 fibromyalgia patients they treated with spironolactone or 12 months. This review addresses two questions: why would pironolactone be effective in reducing fibromyalgia-related sympoms and what is the role of case series in modern medicine. 

Topics from this paper


Long-term efficacy of spironolactone on pain, mood, and quality of life in women with fibromyalgia: An observational case series
It is hypothesised that spironolactone affects several central and peripheral neurotransmitter systems such as γ-aminobutyric acid (GABA) activity and dopaminergic transmission and contributes to pain relief and improvement of associated FHS-symptoms and positive effects on additional diseases or dysfunctions. Expand
Expect analgesic failure; pursue analgesic success
Andrew Moore and colleagues argue that there needs to be a move away from a focus on average response and seek out what works for each patient. Expand
Cetuximab alleviates neuropathic pain despite tumour progression
A direct inhibition of MAPK-signalling by cetuximab in neuronal or glial cells is hypothesised to be an important driver of neuropathic pain in a 68-year-old male patient with metastatic rectal cancer. Expand
Clinical trial of the p38 MAP kinase inhibitor dilmapimod in neuropathic pain following nerve injury
Dilmapimod was well tolerated, with no clinically relevant safety findings, and p38 MAPK inhibitors merit further evaluation for neuropathic pain in larger clinical trials, particularly for clinically meaningful analgesic effect size. Expand
Small fibre pathology in patients with fibromyalgia syndrome.
A reduction in dermal unmyelinated nerve fibre bundles was found in skin samples of patients with fibromyalgia syndrome compared with patients with depression and with healthy control subjects, whereas myelination nerve fibres were spared. Expand
Time-related changes in plasma adrenal steroids during treatment with spironolactone in primary aldosteronism.
The lack of increase in PAC, despite a remarkable rise in PRA and serum potassium, suggests biosynthetic inhibition of spironolactone at the sites of 18-hydroxylation and/or 18-oxidation, because of the elevation of deoxycorticosterone and corticosterone. Expand
Blockade of corticosteroid receptors induces anxiolytic-like effects in streptozotocin-induced diabetic mice, and synergizes with diazepam
The results suggest the participation of corticosteroid receptors in the increased anxiety-like response in diabetic mice and that the blockade of these receptors facilitates the effects of diazepam. Expand
Mineralocorticoid Receptor Blocker Eplerenone Reduces Pain Behaviors In Vivo and Decreases Excitability in Small-diameter Sensory Neurons from Local Inflamed Dorsal Root Ganglia In Vitro
The MR may have a pronociceptive role in the DRG and some of its effects may be mediated by neuronal MR, and may represent a novel therapeutic target in some pain syndromes. Expand
Neuroactive steroids: mechanisms of action and neuropsychopharmacological perspectives
This article describes how these neuroactive steroids modulate neurotransmitter receptors and addresses the neuropsychopharmacological potential that arises from the intracellular crosstalk between genomic and nongenomic steroid effects. Expand
Corticosteroid receptors, macrophages and cardiovascular disease.
The current understanding of the role of corticosteroid receptors in macrophages and their effect on diseases involving inflammation, with a particular focus on cardiovascular disease is discussed. Expand